MIGUEL CORREA: Open Payments
NPI 1710198239 · LEESBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$541 in 22 payments from 9 companies in 2025. Trend: 2023 $1,159 · 2024 $586 · 2025 $541
Food & beverage: $541
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $161 |
| Braeburn Inc. | 4 | $106 |
| Alkermes, Inc. | 3 | $75 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $48 |
| ACADIA Pharmaceuticals Inc | 1 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $41 |
| Neurocrine BioSciences, Inc. | 1 | $27 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
| Janssen Pharmaceuticals, Inc | 1 | $16 |
Products named: CAPLYTA, BRIXADI, REJOYN, VIVITROL, NUPLAZID, AUSTEDO XR, ARISTADA, INGREZZA.
Industry payments across FL — which companies pay providers there.
